Payment & Shipping Terms:
|Usage:||Pitavastatin Calcium Intermediate||CAS:||154057-56-4|
172336 32 2
CAS No . : 154057-56-4 Pitavastatin Intermediate PT-8
Chemical Name : 2 - Cyclopropyl - 4 - ( 4 - fluorophenyl ) - quinolyl - 3 - methylbromide
CAS No . : 154057-65-4
Synonyms : 3 - ( Bromomethyl ) - 2 - cyclopropyl - 4 - ( 4-fluorophenyl ) quinoline ; 3 - ( Bromomethyl ) - 2 - cyclopropyl - 4 - ( 4 ' - fluorophenyl ) quinoline ; 2 - cyclopropan - 3 - bromomethyl 4 - ( 4 - fluorophenyl ) - 3 - quinoline ; 3 - ( Bromomethyl ) - 2 - cyclopropyl - 4 - ( 4 - fluorophenyl ) quinoline
Molecular Formula : C19H15BrFN
Molecular Weight : 356.238
Short code : PT-8
Usage : Pitavastatin Intermediate
Description: Pitavastatin Calcium is the active pharmaceutical ingredient (API) of branded drug Livalo. It was innovated by the Japanese company Nissan Chemical Industries and later Kowa Pharmaceuticals further develop Pitavastatin Calcium. So it was firstly launched in Janan in 2003 and also being marketed in India and South Korea. FDA approved Pitavastatin Calcium in 2009. The UK authority Medicines and Healthcare products Regulatory Agency, also called MHRA, approved it in 2010. Pitavastatin was also previously known as itabavastatin, itavastatin or nisvastatin.
( 2 - Cyclopropyl - 4 - ( 4 - fluorophenyl ) - quinolyl - 3 - methylbromide CAS No . : 154057-65-4 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.
Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.